Development of a platform for spatial functional genomics
Project Number5R01AT011326-05
Former Number1R01OD029988-01
Contact PI/Project LeaderBROWN, BRIAN D
Awardee OrganizationICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Description
Abstract Text
PROJECT SUMMARY
There are >20,000 genes in the genome and though there has been progress in assigning many gene
functions, we still do not know the function of numerous genes or their specific roles in affecting disease. Genes
can direct diverse phenotypes in different cell types, cell states, or tissues, which makes gene annotation a
staggering task. Studies are needed to determine each gene’s function in different contexts, but the scope of the
problem is a challenge – it is necessary to assess many possible functions of 100s of genes and within the
context of a complex cellular and extracellular milieu whose spatial architecture is an essential component of
system behavior. In addition, some genes work coordinately or redundantly with other genes, making phenotypic
annotation more challenging. Establishing the role of every gene in different normal and disease states would
have an incalculable impact on biology and medicine. It would elicit novel intrinsic components of different
diseases and thus facilitate the development of drugs to treat some of these diseases.
The objective of this project is to establish a first-of-its-kind platform for spatial functional genomics (Perturb-
map), which will enable 100s of genetic perturbations, including multi-gene knockouts, to be generated in parallel
in tissues and tumors, and the effect of each perturbation on multiple intrinsic and extrinsic biological processes
to be revealed at cellular, subcellular, and tissue level resolution. To reach our objective, we will develop novel
technologies, methods, and software tools that will permit 100s of CRISPRs, along with dozens of biological
phenotypes, to be spatially resolved within a tissue by high-dimensional imaging. To establish the potential of
Perturb-map to address urgent unmet needs, we will apply the platform to one of the most pressing questions in
immune oncology, namely how tumors prevent immune infiltration and subvert immunity. We will use Perturb-
map to identify factors that regulate immune recruitment and exclusion from the tumor microenvironment and
uncover genes controlling tumor resistance to immune clearance.
The outcome of this project will be a transformative technology for functional genomics with spatial cellular
and sub-cellular resolution and high-dimensional phenotyping. This would have unmatched capabilities to
answer numerous questions in a broad array of biological areas, and to investigate entire classes of genes and
phenotypes that could not be studied with existing functional genomics approaches; enabling highly scaled
studies to identify genes that control processes such as: tissue and tumor organization, cell migration, invasion
and metastasis, cell-cell interactions, and local immune cell recruitment and crosstalk. By being able to
interrogate multiple gene perturbations within the same cell, Perturb-map will also enable genetic redundancies
and synthetic lethal relationships to be identified, a major area of interest for development of targeted cancer
therapies. Thus, the platform will have broad utility in numerous areas of basic and translational biology.
Public Health Relevance Statement
PROJECT NARRATIVE
This project will establish a first-of-its-kind platform for spatial functional genomics (Perturb-map), which will
enable broad phenotypic analysis of 100s of genes in parallel within a tissue or tumor at cellular resolution and
with spatial architecture preserved. This will greatly accelerate functional annotation of the genome and
discovery of tissue and tumor biological control in a manner and scale not currently possible, and thus transform
efforts to uncover the intrinsic components of different diseases and facilitate the development of drugs to treat
these diseases.
National Center for Complementary and Integrative Health
CFDA Code
213
DUNS Number
078861598
UEI
C8H9CNG1VBD9
Project Start Date
01-September-2020
Project End Date
30-June-2025
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$711,098
Direct Costs
$419,527
Indirect Costs
$291,571
Year
Funding IC
FY Total Cost by IC
2024
NIH Office of the Director
$711,098
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AT011326-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AT011326-05
Patents
No Patents information available for 5R01AT011326-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AT011326-05
Clinical Studies
No Clinical Studies information available for 5R01AT011326-05
News and More
Related News Releases
No news release information available for 5R01AT011326-05
History
No Historical information available for 5R01AT011326-05
Similar Projects
No Similar Projects information available for 5R01AT011326-05